Your browser doesn't support javascript.
loading
Risk Factor Analysis of Vancomycin-Induced Nephrotoxicity in Paediatric Patients Aged 0-1 Year Using Japanese Medical Database.
Miyai, Takayuki; Takekuma, Yoh; Kashiwagi, Hitoshi; Sato, Yuki; Nashimoto, Shunsuke; Sugawara, Mitsuru; Imai, Shungo.
Afiliación
  • Miyai T; Graduate School of Life Science, Hokkaido University.
  • Takekuma Y; Department of Pharmacy, Hokkaido University Hospital.
  • Kashiwagi H; Faculty of Pharmaceutical Sciences, Hokkaido University.
  • Sato Y; Faculty of Pharmaceutical Sciences, Hokkaido University.
  • Nashimoto S; Faculty of Pharmaceutical Sciences, Hokkaido University.
  • Sugawara M; Department of Pharmacy, Hokkaido University Hospital.
  • Imai S; Faculty of Pharmaceutical Sciences, Hokkaido University.
Biol Pharm Bull ; 46(6): 817-823, 2023.
Article en En | MEDLINE | ID: mdl-37258147
ABSTRACT
Vancomycin (VCM)-induced nephrotoxicity (VIN) is a major side effect in paediatric patients. However, most studies are limited to patients aged 0-18 years. We evaluated the risk factors of VIN in patients aged 0-1 year using Japanese electronic medical record database. We used RWD database which was contained electronic medical records and claims data of approximately 20 million people from 160 medical institutions. We targeted hospitalized patients who were administered VCM between June 2000 and December 2020. VIN was defined by two criteria Criterion 1 was an increase in serum creatinine (Scr) ≥ 0.5 mg/dL or 50% during VCM treatment period compared to the Scr baseline; and criterion 2 was an increase in Scr ≥50% within seven days or Scr ≥0.3 mg/dL within two days during VCM treatment. The risk factors of VIN were evaluated using multivariate logistic regression analysis. We analysed 446 patients; patients with VIN in Criteria 1 and 2 were 33 and 58, respectively. In Criterion 1, multivariate logistic regression analysis identified four independent factors with p-value <0.05 (VCM concentration ≥20 mg/L, amphotericin B (AMPH-B), piperacillin-tazobactam (TAZ/PIPC), and vasopressor drugs). In Criterion 2, multivariate logistic regression analysis identified concomitant use of vasopressor drugs with p-value <0.05. Therefore, concomitant use of vasopressor drugs was suggested to affect the risk of VIN in patients aged 0-1 year. The findings may help in developing estimation models to assess the risk of VIN in paediatric patients.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Vancomicina / Antibacterianos Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Infant / Newborn Idioma: En Revista: Biol Pharm Bull Asunto de la revista: BIOQUIMICA / FARMACOLOGIA Año: 2023 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Vancomicina / Antibacterianos Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Infant / Newborn Idioma: En Revista: Biol Pharm Bull Asunto de la revista: BIOQUIMICA / FARMACOLOGIA Año: 2023 Tipo del documento: Article